Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?

Nurgul Ozgur Yurttas, MD1 and Ahmet Emre Eskazan, MD1

Keywords
chronic myeloid leukemia, bleeding diathesis, dasatinib, imatinib, platelet dysfunction, tyrosine kinase inhibitor

The management of chronic myeloid leukemia (CML) entirely changed after the emergence of tyrosine kinase inhibitors (TKIs). In the era of TKIs, the 10-year overall survival now exceeds 80%, and the prevalence of patients receiving long-term TKI therapy has substantially increased. In addition to the efficacy, CML caring physicians now mainly focus on the management of the TKI-associated long-term nonhematologic toxicities, generally so-called the “off-target” effects of these drugs.

Second-generation TKIs—dasatinib, nilotinib, and bosutinib—are more potent than imatinib and these drugs also have different off-target multikinase inhibitory effects than imatinib. These adverse events (AEs) may or may not have an impact on the health-related quality of life (HRQoL), especially depending on the grades of these toxicities. The nonhematologic AEs may occur anytime during the follow-up, and sometimes they can have a negative clinical impact.

TKIs are known to be associated with defective platelet function.1,2 Dasatinib, a potent inhibitor of BCR-ABL1 and SRC family kinases (SFK), is known to cause aberrant platelet function and can induce bleeding, independent of thrombocytopenia.2 But many patients with a clinically significant bleeding have low platelet counts and advanced disease phases (eg, blast crisis) that usually require higher daily dasatinib doses.2,3 Platelet function abnormalities have been described to a lesser extent with imatinib and bosutinib, but these laboratory tests generally appear not to be affected by nilotinib because of the different spectrum and intensity of inhibition of off-target signaling pathways by the individual TKIs.1,4 Also, the third-generation TKI, ponatinib, is known to cause atherothrombotic events; on the other hand, it may also impair platelet functions.1,5

In this issue of the Journal, Sener and colleagues6 investigated the possible effects of TKI therapy on platelet functions and other hemostatic parameters in 68 patients with CML in chronic phase (CML-CP) receiving different TKIs. The authors divided their patient cohort into 3 according to the TKI consumed (eg, imatinib [n = 47], dasatinib [n = 15], and nilotinib [n = 6]), and there were no cases with bosutinib nor ponatinib.

For all patients, the platelet counts were >100 × 10^9/L, and only 1.5% of the patients had minimal prolongation in prothrombin time, and 3% of them had minimally prolonged activated partial thromboplastin time. Similar to what was observed in the previous studies performed among patients with CML receiving various TKIs, in this study,6 impaired platelet functions detected by light transmission aggregometry were observed in 29.8%, 40%, and 50% of the patients in imatinib, dasatinib, and nilotinib groups, respectively.

The mechanism of this effect is not fully understood, and Quintás-Cardama and coworkers7 analyzed the impact of TKI therapy on platelet functions via the stimulation of platelet aggregation with adenosine diphosphate, arachidonic acid, epinephrine, collagen, and ristocetin, together with using the platelet function analyzer (PFA-100) in 75 patients with CML-CP. The authors observed that most of the patients receiving dasatinib (23/27, 85%) had platelet dysfunction. Also, they found that 4 (15%) of the 26 patients receiving bosutinib and 10 (66%) of the 15 patients receiving imatinib had impaired platelet function test. On the other hand, they also revealed that all patients treated with nilotinib (n = 7) had normal platelet functions in vitro.

There are other studies reporting TKI—mainly dasatinib-induced platelet dysfunction and the possible underlying mechanisms of this sometimes clinically relevant situation.3,7,8 Dasatinib may alter platelet aggregation by inhibiting key

---

1 Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University–Cerrahpasa, Istanbul, Turkey

Corresponding Author:
Ahmet Emre Eskazan, Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University–Cerrahpasa, Istanbul 34303, Turkey.

Emails: emre.eskazan@hotmail.com; emre.eskazan@istanbul.edu.tr

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
kinases such as SFKs, LYN, and FYN that might play a role in the platelet homeostasis. On the other hand, bosutinib, which is a multikinase inhibitor similar to dasatinib, was detected to cause platelet dysfunction in the study of Quintás-Cardama et al., but no clinically significant bleeding events were reported with bosutinib.

Sener et al. and Quintás-Cardama et al. revealed that impaired platelet functions were observed in 29.8% (14/47) and 66% (10/15) of the cases receiving imatinib, respectively. However, in other studies, imatinib was found not to cause platelet dysfunction. Similarly, nilotinib was generally not associated with platelet dysfunction in vitro, although Sener and colleagues found half of their cases using nilotinib had impaired platelet function tests; however, the number of patients receiving nilotinib in their cohort was very limited. Furthermore, there are some studies reporting that ponatinib may inhibit platelet activation, spreading, granule secretion, and aggregation, likely through broad-spectrum inhibition of platelet tyrosine kinase signaling. These findings are interesting, because as observed in clinical trials, ponatinib may cause atherosclerotic events, although it may also impair platelet functions. So, most probably, there is more to be done in the field of ponatinib-associated thrombotic complications in the future.

Sener and colleagues also tried to objectively quantify the bleeding diagnosis in their cohort using a standardized questionnaire. According to this bleeding questionnaire (the International Society on Thrombosis and Haemostasis/Scientific and Standardization Committee [ISTH/SSC] Bleeding Assessment Tool), 22% (n = 15) of 68 patients had bleeding symptoms. However, all of these bleeding events were minor, including epistaxis, cutaneous bleeding, minor wound bleeding, bleeding after tooth extraction, and menorrhagia. Approximately one-fourth of the cases receiving imatinib and 20% of patients with dasatinib had bleeding symptoms, whereas no patients had bleeding in the nilotinib group. And when compared to cases who had platelet dysfunction, they found no correlation between presence of any bleeding or total bleeding score and plasma secretion defect or any aggregation abnormality. However, Quintás-Cardama et al. revealed that bleeding episodes were observed in 23% of patients with CML treated with dasatinib. This complication was more frequent among those patients with advanced disease who were receiving higher doses of dasatinib and affected the gastrointestinal tract in 81% of the cases, and they emphasized that especially thrombocytopenia and disease status of CML were associated with an increased risk of bleeding. All patients in the cohort of Sener et al. were CML-CP, without any cases with significant thrombocytopenia, and no bleeding in the gastrointestinal tract was observed.

Gastrointestinal tract bleeding is a relatively common treatment-emergent AE in patients receiving dasatinib. Although all patients on dasatinib therapy have a faulty collagen-induced platelet aggregation, only a fraction of them develop clinically significant bleeding complications, with the remaining majority of cases being asymptomatic. In the study of Brave et al., the authors focused on the bleeding tendency of patients receiving dasatinib. Minor bleeding was mostly due to platelet dysfunction plus thrombocytopenia. On the other hand, major bleeding was mainly observed in cases having 2 or more predisposing factors including thrombocytopenia, advanced disease phase, impaired platelet functions, impaired coagulation, and so on. In addition to these predisposing factors, gastrointestinal tract bleeding can also be seen under dasatinib due to hemorrhagic colitis.

Dasatinib is also known to disrupt the barrier function of the vascular endothelium. This transient increase in vascular leakage, enhanced by decreased coated platelet generation—even at low (ie, therapeutic) plasma levels of dasatinib—and impaired platelet aggregation might all contribute to bleeding diathesis. Furthermore, dasatinib has been thought to affect bleeding time and also has an impact on thrombopoiesis, promoting megakaryocyte differentiation within the bone marrow but impairing the ability of megakaryocytes to migrate and form into platelets. In conclusion, according to the present study by Sener et al. and some others, TKIs may cause platelet dysfunction mainly in vitro, which do not necessarily translate into significant clinical outcomes. Especially, dasatinib was shown to have some negative effects on platelet functions, which sometimes may lead to significant bleeding affecting the HRQoL, mainly in the setting of thrombocytopenia and in cases with advanced disease phases. In general, it is not recommended to test for platelet functions prior to or during TKI therapy routinely in CML cases; however, one should always keep in mind that, if a patient with CML under TKI therapy has bleeding diathesis, TKI could be the underlying cause. Thus, in patients with CML having a clinically significant bleeding tendency under TKI treatment, short-term interruption of the therapy could be necessary and beneficial, especially before major surgical procedures.

Acknowledgement
A.E.E. would like to thank Prof. M. Cem Ar for his continuous support and for being a very good colleague and friend.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article: N.O.Y. has no conflict of interest to declare. A.E.E. has received advisory board honorarium from Novartis, and he also received speaker bureau honoraria from Novartis, Bristol-Myers Squibb, and Pfizer outside the present study.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Ahmet Emre Eskazan https://orcid.org/0000-0001-9568-0894
References

1. Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J, Milojkovic D. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. *Haematologica*. 2012;97(9):1444.

2. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. *Blood*. 2009;114(2):261-263.

3. Quintás-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. *Cancer*. 2009;115(11):2482-2490.

4. Gratacap MP, Martin V, Vale MC, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. *Blood*. 2009;114(9):1884-1892.

5. Loren CP, Aslan JE, Rigg RA, et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. *Thromb Res*. 2015;135(1):155-160.

6. Sener Y, Okay M, Aydin S, Buyukasik Y, Akbiyik F, Dikmen ZG. TKI-related platelet dysfunction does not correlate with bleeding in patients with chronic phase-chronic myeloid leukemia with complete hematological response. *Clin Appl Thromb Hemost*. 2019;25. doi:10.1177/1076029619858409.

7. Kreutzman A, Colom-Fernández B, Jiménez AM, et al. Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner. *Clin Cancer Res*. 2017;23(21):6697-6707.

8. Mezei G, Debreceni IB, Kerenyi A, et al. Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia [published online ahead of print August 1, 2018]. *Platelets*. 2018. doi:10.1080/09537104.2018.1501470.

9. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. *Clin Cancer Res*. 2008;14(2):352-359.

10. Eskazan AE, Hatemi I, Öngören Aydin S, Ar MC, Soysal T. Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy. *Turk J Gastroenterol*. 2014;25(suppl 1):233.

11. Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. *Blood*. 2011;117(19):5198-5206.